Healthcare / BiotechnologyKOSDAQ
$1637.00
-73.00 (-4.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-17.2B · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.5%
↓Gross Margin
31.3%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.3%
FCF CAGR
—
FCF margin
-202.0%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.57B · net income $-15.71B · FCF $-7.20B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.57B | $3.57B | $3.36B | $3.13B | $5.29B |
| Net Income | $-15.71B | $-15.71B | $-12.13B | $-21.11B | $-25.95B |
| EBITDA | $-16.37B | $-16.37B | $-9.85B | $-19.83B | $-25.97B |
| EPS | -562.00 | -562.00 | -384.28 | -834.46 | -1035.59 |
| Gross Margin | 31.3% | 31.3% | 34.5% | 60.4% | 51.9% |
| Operating Margin | -276.2% | -276.2% | -395.0% | -866.6% | -455.1% |
| Net Margin | -440.3% | -440.3% | -361.4% | -675.3% | -490.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.05 | 0.03 | 0.04 |
| Current Ratio | 22.91 | 22.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.20B | $-7.20B | $-17.16B | $-21.79B | $-19.47B |
| Returns | |||||
| ROE | -27.5% | -27.5% | -24.1% | -33.4% | -38.9% |
| Valuation | |||||
| P/B | 0.80 | 0.80 | 1.67 | 1.66 | 2.10 |
| Growth & Yield | |||||
| Revenue Growth | 6.3% | 6.3% | 7.4% | -41.0% | — |
| EPS Growth | -46.2% | -46.2% | 53.9% | 19.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-384.28 → -562.00
Residual
-49.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.